IRIS
ZAJA, Francesco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 15.421
AS - Asia 4.967
EU - Europa 3.953
SA - Sud America 1.061
Continente sconosciuto - Info sul continente non disponibili 473
AF - Africa 133
OC - Oceania 7
Totale 26.015
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 15.217
SG - Singapore 2.196
UA - Ucraina 1.179
CN - Cina 1.152
BR - Brasile 810
DE - Germania 633
HK - Hong Kong 545
IT - Italia 517
FI - Finlandia 445
VN - Vietnam 366
RU - Federazione Russa 287
SE - Svezia 256
FR - Francia 196
IE - Irlanda 190
TR - Turchia 139
CA - Canada 112
IN - India 110
GB - Regno Unito 99
AR - Argentina 84
KR - Corea 63
BD - Bangladesh 62
CO - Colombia 56
IQ - Iraq 56
MX - Messico 45
ID - Indonesia 37
EC - Ecuador 35
ZA - Sudafrica 35
IR - Iran 28
MA - Marocco 28
PK - Pakistan 27
ES - Italia 25
JP - Giappone 25
PH - Filippine 24
SA - Arabia Saudita 23
VE - Venezuela 23
BE - Belgio 22
NL - Olanda 17
MY - Malesia 16
UZ - Uzbekistan 15
EU - Europa 14
PY - Paraguay 14
TN - Tunisia 13
KE - Kenya 12
UY - Uruguay 11
CL - Cile 10
JO - Giordania 10
PE - Perù 10
PL - Polonia 10
AE - Emirati Arabi Uniti 9
AT - Austria 9
JM - Giamaica 9
NP - Nepal 9
CH - Svizzera 8
CZ - Repubblica Ceca 8
DZ - Algeria 8
BO - Bolivia 7
PS - Palestinian Territory 7
AL - Albania 6
AU - Australia 6
CR - Costa Rica 6
DO - Repubblica Dominicana 6
EG - Egitto 6
ET - Etiopia 6
NI - Nicaragua 6
RO - Romania 6
RS - Serbia 6
AZ - Azerbaigian 5
KZ - Kazakistan 5
LT - Lituania 5
BH - Bahrain 4
GR - Grecia 4
GT - Guatemala 4
HN - Honduras 4
LB - Libano 4
SN - Senegal 4
AO - Angola 3
BA - Bosnia-Erzegovina 3
BG - Bulgaria 3
GA - Gabon 3
GE - Georgia 3
IL - Israele 3
KG - Kirghizistan 3
KH - Cambogia 3
LV - Lettonia 3
MD - Moldavia 3
PA - Panama 3
TW - Taiwan 3
XK - ???statistics.table.value.countryCode.XK??? 3
CY - Cipro 2
DK - Danimarca 2
HU - Ungheria 2
LU - Lussemburgo 2
OM - Oman 2
PR - Porto Rico 2
PT - Portogallo 2
QA - Qatar 2
SV - El Salvador 2
TG - Togo 2
TH - Thailandia 2
TT - Trinidad e Tobago 2
Totale 25.529
Salva come PNG Salva come JPEG
Città #
Fairfield 1.819
Woodbridge 1.736
Houston 1.149
Ashburn 1.148
Ann Arbor 968
Singapore 826
Jacksonville 769
San Jose 736
Seattle 715
Wilmington 679
Cambridge 617
Beijing 559
Chandler 543
Hong Kong 542
Dearborn 504
Council Bluffs 285
Boardman 241
Princeton 197
Dublin 191
Lauterbourg 168
Munich 162
Los Angeles 143
Udine 131
Ho Chi Minh City 122
Izmir 112
Dallas 111
Santa Clara 109
San Diego 94
Buffalo 78
Helsinki 78
New York 77
São Paulo 77
Hanoi 72
Hefei 67
Redondo Beach 59
Seoul 56
Milan 52
Ogden 47
The Dalles 45
Des Moines 44
Nanjing 37
Norwalk 36
Ottawa 36
Turku 29
Kunming 28
Rio de Janeiro 28
Florence 26
Dong Ket 25
Mumbai 24
Orem 23
Tokyo 22
Montreal 21
Baghdad 20
Johannesburg 20
Atlanta 19
Bogotá 19
Brussels 19
Guangzhou 19
Phoenix 19
Trieste 18
Andover 17
Curitiba 17
San Francisco 17
Toronto 17
Chicago 16
Miano 16
Saint Petersburg 16
Belo Horizonte 15
Boston 15
Shanghai 15
Haiphong 14
Jinan 14
Mexico City 14
Nuremberg 14
Shenyang 14
Da Nang 13
Frankfurt am Main 13
Brasília 12
Dhaka 12
Falls Church 12
Leawood 12
Quito 12
Tashkent 12
Charlotte 11
Chennai 11
Lappeenranta 11
Nanchang 11
Poplar 11
San Mateo 11
Stockholm 11
Warsaw 11
Amman 10
Brooklyn 10
Medellín 10
Porto Alegre 10
Washington 10
Ardabil 9
Denver 9
Pittsburgh 9
Recife 9
Totale 17.119
Salva come PNG Salva come JPEG
Nome #
Long-lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for or failed autologous transplantation 254
Activity of all-trans-retinoic acid in a case of central nervous system extramedullary relapse of acute promyelocytic leukemia 219
Adjuvant treatment with cyclosporin A increases the toxicity of chemotherapy for remission induction in acute non-lymphocytic leukemia. 212
Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial 204
Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases 202
Decreased function of Fas and variations of the perforin gene in adult patients with primary immune thrombocytopenia 200
The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery 194
Low-dose rituximab in adult patients with primary immune thrombocytopenia. 189
ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. 188
Efficacy and safety of rituximab in type II mixed cryoglobulinemia. 182
Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long-term response. 179
Efficacy and safety of rituximab in type II mixed cryoglobulinemia 178
Impact of hepatitis C virus infection on clinical features, quality of life and survival of patients with lymphoplasmacytoid lymphoma/immunocytoma 178
Clonality and phenotype in spleens from patients with primary immune thrombocytopenia. 177
Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centers 176
Earlier administration of Rituximab allows higher rate of long-lasting response in adult patients with autoimmune thrombocytopenia 174
Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection 173
Impact of clinical data on chest radiography sensitivity in detecting pulmonary abnormalities in immunocompromised patients with suspected pneumonia 171
Management of Hodgkin lymphoma in the era of brentuximab vedotin: real-world data from five European countries 171
Management of immune thrombocytopenia in elderly patients 170
BCL-2 immunohistochemical evaluation in B-cell chronic lymphocytic leukemia and hairy cell leukemia before treatment with fludarabine and 2-chloro-deoxy-adenosine 170
153) LAPAROSCOPIC SPLENECTOMY FOR MASSIVELY ENLARGED SPLEENS: TECHNICAL ASPECTS AND RESULTS OF 8 CONSECUTIVE CASES 168
Fludarabine: an active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphoma. 168
Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma 168
Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results 168
Diagnostic framing of IgM monoclonal gammopathy: Focus on Waldenström macroglobulinemia 168
Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. 167
Acute hepatic failure as onset of progressive sclerodermatous chronic graft-versus-host disease after donor lymphocyte infusion. 167
Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials. 167
Nongastrointestinal low-grade mucosa-associated lymphoid tissue lymphoma: analysis of 75 patients. 166
Granulocyte colony-stimulating factor (G-CSF) allows the delivery of effective doses of CHOP and CVP regimens in non-Hodgkin lymphomas. 166
B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. 165
Delayed and long-lasting complete response to fludarabine in two patients with B-cell chronic lymphocytic leukemia. 163
More on false thrombocytopenias: EDTA-dependent pseudothrombocytopenia associated with a congenital platelet release defect. 161
Interim positron emission tomography response-adapted therapy in advanced-stage hodgkin lymphoma: Final results of the phase II part of the HD0801 study 160
Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia. 160
A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi 159
Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT 158
Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura 157
Bendamustine in chronic lymphocytic leukemia: Outcome according to different clinical and biological prognostic factors in the everyday clinical practice. 156
The efficacy of lenalidomide combination therapy in heavily pretreated non-Hodgkin lymphoma patients: an Italian observational, multicenter, retrospective study 156
Peripheral T-cell lymphoma unspecified PTCL-U): a new prognostic model from a retrospective multicentric clinical study 155
Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial 155
Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi 155
Incidence and diagnosis of EDTA-dependent pseudothrombocytopenia in a consecutive outpatient population referred for isolated thrombocytopenia. 154
Allogeneic stem cell transplantation and novel therapies: is the treatment paradigm for younger patients with chronic lymphocytic leukemia changing? 154
CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma 153
B-cell compartment as the selective target for the treatment of immune thrombocytopenias 152
Efficacy of selective B cell Blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells 152
Clinical relevance of the dose of cytarabine in the upfront treatment of primary CNS lymphomas with methotrexate-cytarabine combination. 151
Fludarabine in patients with advanced and/or resistant B-chronic lymphocytic leukemia. 150
Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia 150
Rituximab for the treatment of type II mixed cryoglobulinemia 149
High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: A retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO 149
T-cell chimerism and clinical outcome after reduced-intensity conditioning allogeneic stem cell transplantation 147
Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia 147
The SIRT1/TP53 axis is activated upon B-cell receptor triggering via miR-132 up-regulation in chronic lymphocytic leukemia cells 147
Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations 147
Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials 147
Nongastric marginal-zone B-cell MALT lymphoma: prognostic value of disease dissemination 146
Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: A phase II clinical trial of the fondazione italiana linfomi 146
Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana Linfomi. 145
Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia 145
Quantitative PCR of bone marrow BCL2/IgH+ cells at diagnosis predicts treatment response and long-term outcome in follicular non-Hodgkin lymphoma 144
KERATOCONJUNCTIVITIS TREATMENT WITH AUTOLOGOUS SERUM EYE IN PATIENTS WITH SEVERE CHRONIC GVHD 144
The role of Rituximab in the therapy of mixed cryoglobulinemia 144
Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 10th annual conference of the European Mantle Cell Lymphoma Network. 144
MATILDE chemotherapy regimen for primary CNS lymphoma: results at a median follow-up of 12 years. 142
CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia 142
Combined therapy with Fludarabine and cyclophosphamide in relapsed/resistant patients with B-cell chronic lymphocytic leukaemia and non-Hodgkin's lymphomas. 141
Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia 141
MYC protein expression scoring and its impact on the prognosis of aggressive B-cell lymphoma patients 141
Surgical staging in Hodgkin's disease: the role of laparoscopic splenectomy 140
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program. 140
Sustained response to low-dose rituximab in idiopathic autoimmune hemolytic anemia. 140
Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biologic studies. 139
NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dysregulation 139
Occurrence of multiple myeloma after fludarabine treatment of a chronic lymphocytic leukemia: evidence of a biclonal derivation and clinical response to autologous transplantation 138
Intensified full-dose induction therapy (HD-MACHOP+radiotherapy) follwed dy consolidation with BAVC regimen and autologous stem cell transplantation as fron-line therapeutic approach for high risk aggressive non Hodgkin lymphoma 138
Dapsone salvage therapy for adult patients with immune thrombocytopenia relapsed or refractory to steroid and rituximab. 138
Brentuximab vedotin in combination with extended field radiotherapy as salvage treatment for primary refractory Hodgkin lymphoma. 138
Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia 138
Successful treatment and FDG-PET/CT monitoring of HHV-6 encephalitis in a non-neutropenic patient: case report and literature review 138
Rituximab-responsive CIDP. 138
The role of granulocyte colony-stimulating factor (filgrastim) in maintaining dose intensity during conventional-dose chemotherapy with ABVD in Hodgkin's disease. 137
The spectrum of Evans syndrome in adults: new insight into the disease based on the analysis of 68 cases. 137
Molecular prediction of durable remission after first-line fludarabinecyclophosphamide-rituximab in chronic lymphocytic leukemia 137
Temozolomide as salvage treatment in primary brain lymphomas 136
A retrospective analysis of 144 patients with aggressive non-Hodgkin's lymphoma: impact of aurtologoaus stem cell transplantation in first remission on autcome 135
Nocardiosis with favourable clinical outcome in progressive B-chronic lymphocytic leukaemia 135
Sequential intensive treatment with the F-MACHOP regimen (+/- radiotherapy) and autologous stem cell transplantation for primary systemic CD30 (Ki-1)--positive anaplastic large cell lymphoma in adults. 134
A diachronic-comparative analysis for the identification of the most powerful prognostic index for localized diffuse large B-cell lymphoma. 134
New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment? 134
Mutational status of IGHV is the most reliable prognostic marker in trisomy 12 chronic lymphocytic leukemia 134
NOTCH1 mutational status in chronic lymphocytic leukaemia: Clinical relevance of subclonal mutations and mutation types 134
Gemcitabine as frontline treatment for cutaneous T-cell lymphoma. Phase II study of 32 patients 134
Hepatitis C virus infection among cryoglobulinemic and non-cryoglobulinemic B-cell non-Hodgkin’s lymphomas 133
Indolent B-cell lymphomas associated with HCV infection: clinical and virological features and role of antiviral therapy. 133
No evidence for B-cell clonality by spectratyping analysis in patients with idiopathic thrombocytopenic purpura undergoing rituximab therapy” 132
MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas 132
Totale 15.623
Salva come PNG Salva come JPEG
Categoria #
all - tutte 94.687
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 94.687
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.340 0 0 71 109 52 78 100 87 15 261 303 264
2022/20231.323 214 72 20 135 141 398 0 91 171 18 34 29
2023/2024381 60 22 10 14 69 46 22 14 65 25 15 19
2024/20253.199 52 252 154 66 120 168 214 204 342 261 466 900
2025/20265.670 378 649 501 523 825 451 689 186 430 518 358 162
2026/20271.153 118 521 514 0 0 0 0 0 0 0 0 0
Totale 26.015